Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis
admin 19th April 2018 Uncategorised 0Novartis’s first-quarter sales and earnings beat consensus analyst estimates. So why did the company’s stock dip more than 2% first thing Thursday? The answer speaks to investors’ high expectations for its new CEO, Vas Narasimhan—and for his promise to focus on markets that can drive earnings growth the most.
More: Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis
Source: fierce